Guidelines for the diagnosis, screening, and treatment of osteoporosis in women

Advanced Studies in Medicine

Volumn 5, Issue 10, 2005, Pages 518-523

  Allen, Michele L ^a,b   Wyatt, Lacey E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Family Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMG 162; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTRADIOL; ESTROGEN; GESTAGEN; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STATINE DERIVATIVE; VITAMIN D; ZOLEDRONIC ACID;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; EXERCISE; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HUMAN; LABORATORY TEST; LIFESTYLE; LOW DRUG DOSE; MASS SCREENING; MEDICAL DECISION MAKING; META ANALYSIS; MORBIDITY; MORTALITY; OSTEOPOROSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PREMENOPAUSE; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT PLANNING; UNITED STATES; WEIGHT BEARING;

EID: 33644688151     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. US Department of Health and Human Services. Executive Summary. Bone Health and Osieoporosis: A Report of the Surgeon General. Rackville, Md: Department af Health and Human Services, Office of the Surgeon General; 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth. Accessed October 17, 2005.
2. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
3. Fulton JP. New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health R I. 1999;82:110-111.
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
5. Schott AM, Weill-Engerer S, Hans D, Duboeuf F, Delmas PD, Meunier PJ. Ultrasound discriminates patients with hip fracture equally well as dual energy x-ray absorptiometry and independently of bone mineral density. J Bone Miner Res. 1995;10:243-249.
6. National Osteoporosis Foundation. About osteoporosis: fast facts. National Osteoporosis Foundation Web site. Available at: http://www.nof.org/ osteoporosis/diseasefacts.htm. Accessed October 17, 2005.
7. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
8. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. DRI Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vifamin D, and Fluoride. Washington, DC: National Academy Press; 1996.
9. NIH Consensus Development Panel on Optimal Calcium Intake. NIH Consensus conference: optimal calcium intake. JAMA. 1994;272:1942-1948.
10. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003;18:343-351.
11. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113-1118.
12. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. J Nutr. 2005;135:310-316.
13. Hadgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-504.
14. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. Rates of bone loss in postmenopausal warnen randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr. 1995;61:1140-1145.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002;288:321-333.
16. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions. Recommendations and rationale. Am Fam Physician. 2003;67:358-364.
17. American College of Obstetricians and Gynecologists, Women's Healthcare Physicians. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004;103:203-216.
18. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443-451.
19. Menostar: a low-dose estrogen patch for osteoporosis. Obstet Gynecol. 2005;105:432-433.
20. Hodsman AB, Bauer DC, Dempster DW, etal. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence ond suggested guidelines for its use. Endocr Rev. 2005;26:688-703.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausol women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
22. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
23. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.
24. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-152.
25. Koval PG, Easterling L, Pettus D, Mackler L, Gottschall AB. Clinical inquiries: how should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? J Fam Pract. 2005;54:65, 69-71.
26. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29-37.
27. Camera P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1093-1700.
28. Hochberg MC, Greenspan S, Wasnich RD, Milier P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
29. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess (Summ) [online]. 2001(28):1-2. Available at: http://www.ncbi.nlm.nih.gov/books. HSTAT: Evidence Report # 28. Accessed October 17, 2005.